OsmanKostekMD· @OncologyMarwarD · X·· 2 days agoScore70
Body
🚨 ESMO26 | G-HOPE-001
Arcotatug tavatecan vs chemotherapy in CLDN18.2-high advanced gastric/GEJ cancer (3L+):
✅ PFS: HR 0.47
✅ OS: 10.2 vs 6.9 months (HR 0.57)
🎯 Promising new option for heavily pretreated patients!
#ESMO26 #GastricCancer #ADC
215 views · 4 likes · 1 repost · 0 replies
Conference abstracts
LBA77matched by Proffered paper 1: Gastrointestinal tumour, upper digestive
Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G
https://esmocongress.esmo.orgSource: OsmanKostekMD · x.com